Studies have shown that mTOR inhibitors, such as AZD8055, can downregulate FANCD2 expression, reduce ATM/Chk2 activity, and weaken the repair capacity of the Fanconi anemia pathway, thereby exacerbating DNA damage accumulation. The gene discussed is ATM; the disease is Fanconi anemia.